Brain-derived neurotrophic factor and autism: maternal and infant peripheral blood levels in the Early Markers for Autism (EMA) study / Lisa A. CROEN in Autism Research, 1-2 (April 2008)  

Public ISBD [article]  inAutism Research > 1-2 (April 2008) . - p.130-137 Titre : Brain-derived neurotrophic factor and autism: maternal and infant peripheral blood levels in the Early Markers for Autism (EMA) study Type de document : Texte imprimé et/ou numérique Auteurs : Lisa A. CROEN, Auteur ; David J. HANSEN, Auteur ; Martin KHARRAZI, Auteur ; Bruce FIREMAN, Auteur ; Cathleen K. YOSHIDA, Auteur ; Robert YOLKEN, Auteur ; Daniel BRAUNSCHWEIG, Auteur ; Paula GOINES, Auteur ; Judy VAN DE WATER, Auteur ; Judith K. GRETHER, Auteur Année de publication : 2008 Article en page(s) : p.130-137 Langues : Anglais (eng) Mots-clés : biologic-markers neurotrophin autism BDNF prenatal Index. décimale : PER Périodiques Résumé : To investigate levels of brain-derived neurotrophic factor (BDNF) in mid-pregnancy and neonatal blood specimens as early biologic markers for autism, we conducted a population-based case-control study nested within the cohort of infants born from July 2000 to September 2001 to women who participated in the prenatal screening program in Orange County, CA. Cases (n=84) were all children receiving services for autism at the Regional Center of Orange County. Two comparison groups from the same study population were included: children with mental retardation or developmental delay (n=49) receiving services at the same regional center, and children not receiving services for developmental disabilities, randomly sampled from the California birth certificate files (n=159), and frequency matched to autism cases on sex, birth year, and birth month. BDNF concentrations were measured in archived mid-pregnancy and neonatal blood specimens drawn during routine prenatal and newborn screening using a highly sensitive bead-based assay (Luminex, Biosource Human BDNF Antibody Bead Kit, Invitrogen-Biosource, Carlsbad, CA). The concentration of BDNF in maternal mid-pregnancy and neonatal specimens was similar across all three study groups. These data do not support previous findings of an association between BDNF and autism and suggest that the concentration of BDNF during critical periods of early neurodevelopment is not likely to be a useful biomarker for autism susceptibility. En ligne : http://dx.doi.org/10.1002/aur.14 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=930 [article] Brain-derived neurotrophic factor and autism: maternal and infant peripheral blood levels in the Early Markers for Autism (EMA) study [Texte imprimé et/ou numérique] / Lisa A. CROEN, Auteur ; David J. HANSEN, Auteur ; Martin KHARRAZI, Auteur ; Bruce FIREMAN, Auteur ; Cathleen K. YOSHIDA, Auteur ; Robert YOLKEN, Auteur ; Daniel BRAUNSCHWEIG, Auteur ; Paula GOINES, Auteur ; Judy VAN DE WATER, Auteur ; Judith K. GRETHER, Auteur . - 2008 . - p.130-137. Langues : Anglais (eng) in Autism Research > 1-2 (April 2008) . - p.130-137 Mots-clés : biologic-markers neurotrophin autism BDNF prenatal Index. décimale : PER Périodiques Résumé : To investigate levels of brain-derived neurotrophic factor (BDNF) in mid-pregnancy and neonatal blood specimens as early biologic markers for autism, we conducted a population-based case-control study nested within the cohort of infants born from July 2000 to September 2001 to women who participated in the prenatal screening program in Orange County, CA. Cases (n=84) were all children receiving services for autism at the Regional Center of Orange County. Two comparison groups from the same study population were included: children with mental retardation or developmental delay (n=49) receiving services at the same regional center, and children not receiving services for developmental disabilities, randomly sampled from the California birth certificate files (n=159), and frequency matched to autism cases on sex, birth year, and birth month. BDNF concentrations were measured in archived mid-pregnancy and neonatal blood specimens drawn during routine prenatal and newborn screening using a highly sensitive bead-based assay (Luminex, Biosource Human BDNF Antibody Bead Kit, Invitrogen-Biosource, Carlsbad, CA). The concentration of BDNF in maternal mid-pregnancy and neonatal specimens was similar across all three study groups. These data do not support previous findings of an association between BDNF and autism and suggest that the concentration of BDNF during critical periods of early neurodevelopment is not likely to be a useful biomarker for autism susceptibility. En ligne : http://dx.doi.org/10.1002/aur.14 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=930

Increased mid-gestational IFN-gamma, IL-4, and IL-5 in women giving birth to a child with autism: a case-control study / Paula GOINES in Molecular Autism, (August 2011)  

Public ISBD [article]  inMolecular Autism > (August 2011) . - 41 p. Titre : Increased mid-gestational IFN-gamma, IL-4, and IL-5 in women giving birth to a child with autism: a case-control study Type de document : Texte imprimé et/ou numérique Auteurs : Paula GOINES, Auteur ; Lisa A. CROEN, Auteur ; Daniel BRAUNSCHWEIG, Auteur ; Cathleen K. YOSHIDA, Auteur ; Judith K. GRETHER, Auteur ; David J. HANSEN, Auteur ; Martin KHARRAZI, Auteur ; Paul ASHWOOD, Auteur ; Judy VAN DE WATER, Auteur Année de publication : 2011 Article en page(s) : 41 p. Langues : Anglais (eng) Index. décimale : PER Périodiques Résumé : Background Immune anomalies have been documented in individuals with autism spectrum disorders (ASDs) and their family members. It is unknown whether the maternal immune profile during pregnancy is associated with the risk of bearing a child with ASD or other neurodevelopmental disorders. Methods Using Luminex technology, levels of 17 cytokines and chemokines were measured in banked serum collected from women at 15 to 19 weeks of gestation who gave birth to a child ultimately diagnosed with (1) ASD (n = 84), (2) a developmental delay (DD) but not autism (n = 49) or (3) no known developmental disability (general population (GP); n = 159). ASD and DD risk associated with maternal cytokine and chemokine levels was estimated by using multivariable logistic regression analysis. Results Elevated concentrations of IFN-gamma, IL-4 and IL-5 in midgestation maternal serum were significantly associated with a 50% increased risk of ASD, regardless of ASD onset type and the presence of intellectual disability. By contrast, elevated concentrations of IL-2, IL-4 and IL-6 were significantly associated with an increased risk of DD without autism. Conclusion The profile of elevated serum IFN-gamma, IL-4 and IL-5 was more common in women who gave birth to a child subsequently diagnosed with ASD. An alternative profile of increased IL-2, IL-4 and IL-6 was more common for women who gave birth to a child subsequently diagnosed with DD without autism. Further investigation is needed to characterize the relationship between these divergent maternal immunological phenotypes and to evaluate their effect on neurodevelopment. En ligne : http://dx.doi.org/10.1186/2040-2392-2-13 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=141 [article] Increased mid-gestational IFN-gamma, IL-4, and IL-5 in women giving birth to a child with autism: a case-control study [Texte imprimé et/ou numérique] / Paula GOINES, Auteur ; Lisa A. CROEN, Auteur ; Daniel BRAUNSCHWEIG, Auteur ; Cathleen K. YOSHIDA, Auteur ; Judith K. GRETHER, Auteur ; David J. HANSEN, Auteur ; Martin KHARRAZI, Auteur ; Paul ASHWOOD, Auteur ; Judy VAN DE WATER, Auteur . - 2011 . - 41 p. Langues : Anglais (eng) in Molecular Autism > (August 2011) . - 41 p. Index. décimale : PER Périodiques Résumé : Background Immune anomalies have been documented in individuals with autism spectrum disorders (ASDs) and their family members. It is unknown whether the maternal immune profile during pregnancy is associated with the risk of bearing a child with ASD or other neurodevelopmental disorders. Methods Using Luminex technology, levels of 17 cytokines and chemokines were measured in banked serum collected from women at 15 to 19 weeks of gestation who gave birth to a child ultimately diagnosed with (1) ASD (n = 84), (2) a developmental delay (DD) but not autism (n = 49) or (3) no known developmental disability (general population (GP); n = 159). ASD and DD risk associated with maternal cytokine and chemokine levels was estimated by using multivariable logistic regression analysis. Results Elevated concentrations of IFN-gamma, IL-4 and IL-5 in midgestation maternal serum were significantly associated with a 50% increased risk of ASD, regardless of ASD onset type and the presence of intellectual disability. By contrast, elevated concentrations of IL-2, IL-4 and IL-6 were significantly associated with an increased risk of DD without autism. Conclusion The profile of elevated serum IFN-gamma, IL-4 and IL-5 was more common in women who gave birth to a child subsequently diagnosed with ASD. An alternative profile of increased IL-2, IL-4 and IL-6 was more common for women who gave birth to a child subsequently diagnosed with DD without autism. Further investigation is needed to characterize the relationship between these divergent maternal immunological phenotypes and to evaluate their effect on neurodevelopment. En ligne : http://dx.doi.org/10.1186/2040-2392-2-13 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=141

Reduced levels of immunoglobulin in children with autism correlates with behavioral symptoms / Luke HEUER in Autism Research, 1-5 (October 2008)  

Public ISBD [article]  inAutism Research > 1-5 (October 2008) . - p.275-283 Titre : Reduced levels of immunoglobulin in children with autism correlates with behavioral symptoms Type de document : Texte imprimé et/ou numérique Auteurs : Luke HEUER, Auteur ; David J. HANSEN, Auteur ; Joseph SCHAUER, Auteur ; Paula GOINES, Auteur ; Paul ASHWOOD, Auteur ; Judy VAN DE WATER, Auteur ; Isaac N. PESSAH, Auteur ; Paula KRAKOWIAK, Auteur ; Irva HERTZ-PICCIOTTO, Auteur ; Lisa A. CROEN, Auteur Année de publication : 2008 Article en page(s) : p.275-283 Langues : Anglais (eng) Mots-clés : Autism immunoglobulin behavior IgG Index. décimale : PER Périodiques Résumé : Objectives: To assay if plasma antibody levels in children with autism or developmental delays (DD) differ from those with typical development as an indicator of immune function and to correlate antibody levels with severity of behavioral symptoms. Methods: Plasma was collected from children with autistic disorder (AU; n=116), DD but not autism (n=32), autism spectrum disorder but not full autism (n=27), and age-matched typically developing (TD) controls (n=96). Samples were assayed for systemic levels of immunoglobulin (IgG, IgM, IgA, and IgE) by enzyme-linked immunosorbent assay. Subjects with autism were evaluated using the Autism Diagnostic Observation Schedule and the Autism Diagnostic Interview - Revised, and all subjects were scored on the Aberrant Behavior Checklist (ABC) by the parents. Numerical scores for each of the ABC subscales as well as the total scores were then correlated with Ig levels. Results: Children with AU have a significantly reduced level of plasma IgG (5.39±0.29 mg/mL) compared to the TD (7.72±0.28 mg/mL; P<0.001) and DD children (8.23±0.49 mg/mL; P<0.001). Children with autism also had a reduced level of plasma IgM (0.670.06mg/mL) compared to TD (0.79±0.05 mg/mL; P<0.05). Ig levels were negatively correlated with ABC scores for all children (IgG: r=-0.334, P<0.0001; IgM: r=-0.167, P=0.0285). Conclusion: Children with AU have significantly reduced levels of plasma IgG and IgM compared to both DD and TD controls, suggesting an underlying defect in immune function. This reduction in specific Ig levels correlates with behavioral severity, where those patients with the highest scores in the behavioral battery have the most reduced levels of IgG and IgM. En ligne : http://dx.doi.org/10.1002/aur.42 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=933 [article] Reduced levels of immunoglobulin in children with autism correlates with behavioral symptoms [Texte imprimé et/ou numérique] / Luke HEUER, Auteur ; David J. HANSEN, Auteur ; Joseph SCHAUER, Auteur ; Paula GOINES, Auteur ; Paul ASHWOOD, Auteur ; Judy VAN DE WATER, Auteur ; Isaac N. PESSAH, Auteur ; Paula KRAKOWIAK, Auteur ; Irva HERTZ-PICCIOTTO, Auteur ; Lisa A. CROEN, Auteur . - 2008 . - p.275-283. Langues : Anglais (eng) in Autism Research > 1-5 (October 2008) . - p.275-283 Mots-clés : Autism immunoglobulin behavior IgG Index. décimale : PER Périodiques Résumé : Objectives: To assay if plasma antibody levels in children with autism or developmental delays (DD) differ from those with typical development as an indicator of immune function and to correlate antibody levels with severity of behavioral symptoms. Methods: Plasma was collected from children with autistic disorder (AU; n=116), DD but not autism (n=32), autism spectrum disorder but not full autism (n=27), and age-matched typically developing (TD) controls (n=96). Samples were assayed for systemic levels of immunoglobulin (IgG, IgM, IgA, and IgE) by enzyme-linked immunosorbent assay. Subjects with autism were evaluated using the Autism Diagnostic Observation Schedule and the Autism Diagnostic Interview - Revised, and all subjects were scored on the Aberrant Behavior Checklist (ABC) by the parents. Numerical scores for each of the ABC subscales as well as the total scores were then correlated with Ig levels. Results: Children with AU have a significantly reduced level of plasma IgG (5.39±0.29 mg/mL) compared to the TD (7.72±0.28 mg/mL; P<0.001) and DD children (8.23±0.49 mg/mL; P<0.001). Children with autism also had a reduced level of plasma IgM (0.670.06mg/mL) compared to TD (0.79±0.05 mg/mL; P<0.05). Ig levels were negatively correlated with ABC scores for all children (IgG: r=-0.334, P<0.0001; IgM: r=-0.167, P=0.0285). Conclusion: Children with AU have significantly reduced levels of plasma IgG and IgM compared to both DD and TD controls, suggesting an underlying defect in immune function. This reduction in specific Ig levels correlates with behavioral severity, where those patients with the highest scores in the behavioral battery have the most reduced levels of IgG and IgM. En ligne : http://dx.doi.org/10.1002/aur.42 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=933

The Immune System, Autoimmunity, Allergy, and Autism Spectrum Disorders / Paula GOINES

Public ISBD in Autism Spectrum Disorders / David G. AMARAL Titre : The Immune System, Autoimmunity, Allergy, and Autism Spectrum Disorders Type de document : Texte imprimé et/ou numérique Auteurs : Paula GOINES, Auteur ; Andrew W. ZIMMERMAN, Auteur ; Paul ASHWOOD, Auteur ; Judy VAN DE WATER, Auteur Année de publication : 2011 Importance : p.395-419 Langues : Anglais (eng) Index. décimale : AUT-B AUT-B - L'Autisme - Ouvrages généraux et scientifiques Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=139 in Autism Spectrum Disorders / David G. AMARAL The Immune System, Autoimmunity, Allergy, and Autism Spectrum Disorders [Texte imprimé et/ou numérique] / Paula GOINES, Auteur ; Andrew W. ZIMMERMAN, Auteur ; Paul ASHWOOD, Auteur ; Judy VAN DE WATER, Auteur . - 2011 . - p.395-419. Langues : Anglais (eng) Index. décimale : AUT-B AUT-B - L'Autisme - Ouvrages généraux et scientifiques Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=139

Exemplaires

Code-barres	Cote	Support	Localisation	Section	Disponibilité
aucun exemplaire

---

1 (1 - 4 / 4)